ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock News

NASDAQ:ARQT - Nasdaq - US03969K1088 - Common Stock - Currency: USD

14.55 +0.21 (+1.46%)

Premarket: 14.55 0 (0%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARQT Latest News, Press Relases and Analysis

All

Press Releases

20 days ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

a month ago - By: Yahoo Finance - Mentions: VZ AMZN WMT CADE ...

How Cadence Bank, Kimberly-Clark, And Robert Half Can Put Cash In Your Pocket

a month ago - By: Yahoo Finance - Mentions: UBS KR UNP DE ...

UBS Maintains Neutral on Kroger Ahead of Earnings, Sees Balanced Risk-Reward Outlook

2 months ago - By: Benzinga

Analyst Expectations For Arcutis Biotherapeutics's Future

3 months ago - By: Benzinga - Mentions: ENLT SSL ATKR GPOR ...

Earnings Scheduled For May 6, 2025

a month ago - By: Yahoo Finance - Mentions: BLND SNY NVDA TSM ...

Covius Services to Acquire Blend Labs’ (BLND) Title365 Holding Co

a month ago - By: Yahoo Finance - Mentions: ELV ACGL AGIO AZN ...

Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating

a month ago - By: Yahoo Finance - Mentions: SPRY MEOH GSC KR ...

Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier”

a month ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

2 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

2 months ago - By: Arcutis Biotherapeutics, Inc.

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

2 months ago - By: Arcutis Biotherapeutics, Inc.

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology

3 months ago - By: Zacks Investment Research - Mentions: SABS

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Zacks Investment Research - Mentions: QGEN

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

3 months ago - By: Zacks Investment Research - Mentions: ALKS

Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

3 months ago - By: Zacks Investment Research

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Chief Financial Officer Transition

3 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis Announces Chief Financial Officer Transition

4 months ago - By: Yahoo Finance - Mentions: UWMC RKT HD COOP

Why UWM Holdings Corp. (UWMC) Went Up On Wednesday?

4 months ago - By: Yahoo Finance

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis and Padagis Agree to Stay Patent Lawsuit

4 months ago - By: Arcutis Biotherapeutics, Inc.

Arcutis and Padagis Agree to Stay Patent Lawsuit